Shanghai Kaibao PharmaceuticalLtd Past Earnings Performance
Past criteria checks 5/6
Shanghai Kaibao PharmaceuticalLtd has been growing earnings at an average annual rate of 16.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 6.6% per year. Shanghai Kaibao PharmaceuticalLtd's return on equity is 9%, and it has net margins of 22.3%.
Key information
16.1%
Earnings growth rate
16.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 6.6% |
| Return on equity | 9.0% |
| Net Margin | 22.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Kaibao PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,561 | 349 | 808 | 121 |
| 30 Jun 24 | 1,577 | 335 | 835 | 112 |
| 31 Mar 24 | 1,610 | 336 | 850 | 104 |
| 31 Dec 23 | 1,594 | 328 | 853 | 96 |
| 30 Sep 23 | 1,473 | 268 | 768 | 94 |
| 30 Jun 23 | 1,425 | 243 | 772 | 87 |
| 31 Mar 23 | 1,234 | 213 | 681 | 67 |
| 01 Jan 23 | 1,119 | 191 | 620 | 53 |
| 30 Sep 22 | 1,106 | 143 | 642 | 83 |
| 30 Jun 22 | 1,103 | 141 | 638 | 80 |
| 31 Mar 22 | 1,104 | 141 | 660 | 72 |
| 01 Jan 22 | 1,101 | 140 | 656 | 79 |
| 30 Sep 21 | 1,055 | 116 | 682 | 50 |
| 30 Jun 21 | 970 | 111 | 614 | 60 |
| 31 Mar 21 | 954 | 111 | 601 | 67 |
| 31 Dec 20 | 908 | 106 | 580 | 59 |
| 30 Sep 20 | 1,003 | 148 | 593 | 58 |
| 30 Jun 20 | 1,107 | 175 | 666 | 52 |
| 31 Mar 20 | 1,312 | 232 | 765 | 53 |
| 31 Dec 19 | 1,419 | 251 | 829 | 55 |
| 30 Sep 19 | 1,414 | 197 | 848 | 52 |
| 30 Jun 19 | 1,382 | 197 | 821 | 38 |
| 31 Mar 19 | 1,380 | 199 | 824 | 32 |
| 31 Dec 18 | 1,501 | 227 | 886 | 47 |
| 30 Sep 18 | 1,466 | 246 | 881 | 65 |
| 30 Jun 18 | 1,543 | 261 | 884 | 100 |
| 31 Mar 18 | 1,633 | 281 | 937 | 90 |
| 31 Dec 17 | 1,570 | 272 | 894 | 65 |
| 30 Sep 17 | 1,557 | 287 | 877 | 32 |
| 30 Jun 17 | 1,546 | 286 | 904 | 0 |
| 31 Mar 17 | 1,524 | 290 | 891 | 0 |
| 31 Dec 16 | 1,497 | 283 | 880 | 0 |
| 30 Sep 16 | 1,444 | 287 | 840 | 0 |
| 30 Jun 16 | 1,398 | 284 | 814 | 0 |
| 31 Mar 16 | 1,368 | 274 | 809 | 0 |
| 31 Dec 15 | 1,396 | 282 | 832 | 0 |
| 30 Sep 15 | 1,536 | 331 | 899 | 0 |
| 30 Jun 15 | 1,633 | 357 | 953 | 0 |
| 31 Mar 15 | 1,700 | 363 | 992 | 0 |
| 31 Dec 14 | 1,621 | 352 | 945 | 0 |
| 30 Sep 14 | 1,511 | 345 | 880 | 0 |
| 30 Jun 14 | 1,481 | 337 | 864 | 0 |
| 31 Mar 14 | 1,371 | 330 | 797 | 0 |
| 31 Dec 13 | 1,323 | 319 | 777 | 0 |
Quality Earnings: 300039 has high quality earnings.
Growing Profit Margin: 300039's current net profit margins (22.3%) are higher than last year (18.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300039's earnings have grown by 16.1% per year over the past 5 years.
Accelerating Growth: 300039's earnings growth over the past year (30%) exceeds its 5-year average (16.1% per year).
Earnings vs Industry: 300039 earnings growth over the past year (30%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 300039's Return on Equity (9%) is considered low.